Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm

被引:29
作者
Bertrand, Julie [1 ]
Comets, Emmanuelle [1 ]
Laffont, Celine M. [2 ]
Chenel, Marylore [3 ]
Mentre, France [1 ]
机构
[1] Univ Paris Diderot, INSERM, UMR 738, F-75018 Paris, France
[2] ENVT, INRA, UMR Physiol & Toxicol Expt 181, Toulouse, France
[3] Inst Rech Int Servier, F-92415 Courbevoie, France
关键词
Pharmacogenetics; Pharmacokinetics; Nonlinear mixed effects models; Test; Design; Single nucleotid polymorphism; SAEM; MIXED-EFFECTS MODELS; GENETIC POLYMORPHISMS; MDR1; SELECTION; SOFTWARE; CYP3A5; POWER;
D O I
10.1007/s10928-009-9124-x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacogenetics is now widely investigated and health institutions acknowledge its place in clinical pharmacokinetics. Our objective is to assess through a simulation study, the impact of design on the statistical performances of three different tests used for analysis of pharmacogenetic information with nonlinear mixed effects models: (i) an ANOVA to test the relationship between the empirical Bayes estimates of the model parameter of interest and the genetic covariate, (ii) a global Wald test to assess whether estimates for the gene effect are significant, and (iii) a likelihood ratio test (LRT) between the model with and without the genetic covariate. We use the stochastic EM algorithm (SAEM) implemented in MONOLIX 2.1 software. The simulation setting is inspired from a real pharmacokinetic study. We investigate four designs with N the number of subjects and n the number of samples per subject: (i) N = 40/n = 4, similar to the original study, (ii) N = 80/n = 2 sorted in 4 groups, a design optimized using the PFIM software, (iii) a combined design, N = 20/n = 4 plus N = 80 with only a trough concentration and (iv) N = 200/n = 4, to approach asymptotic conditions. We find that the ANOVA has a correct type I error estimate regardless of design, however the sparser design was optimized. The type I error of the Wald test and LRT are moderatly inflated in the designs far from the asymptotic (< 10%). For each design, the corrected power is analogous for the three tests. Among the three designs with a total of 160 observations, the design N = 80/n = 2 optimized with PFIM provides both the lowest standard error on the effect coefficients and the best power for the Wald test and the LRT while a high shrinkage decreases the power of the ANOVA. In conclusion, a correction method should be used for model-based tests in pharmacogenetic studies with reduced sample size and/or sparse sampling and, for the same amount of samples, some designs have better power than others.
引用
收藏
页码:317 / 339
页数:23
相关论文
共 45 条
  • [1] Ways to fit a PK model with some data below the quantification limit
    Beal, SL
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (05) : 481 - 504
  • [2] Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters
    Bertrand, Julie
    Comets, Emmanuelle
    Mentre, France
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2008, 18 (06) : 1084 - 1102
  • [3] Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART
    Bertrand, Julie
    Treluyer, Jean-Marc
    Panhard, Xaviere
    Tran, Agnes
    Auleley, Solange
    Rey, Elisabeth
    Salmon-Ceron, Dominique
    Duval, Xavier
    Mentre, France
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (07) : 667 - 678
  • [4] Covariate detection in population pharmacokinetics using partially linear mixed effects models
    Bonate, PL
    [J]. PHARMACEUTICAL RESEARCH, 2005, 22 (04) : 541 - 549
  • [5] SOME THEOREMS ON QUADRATIC FORMS APPLIED IN THE STUDY OF ANALYSIS OF VARIANCE PROBLEMS .1. EFFECT OF INEQUALITY OF VARIANCE IN THE ONE-WAY CLASSIFICATION
    BOX, GEP
    [J]. ANNALS OF MATHEMATICAL STATISTICS, 1954, 25 (02): : 290 - 302
  • [6] BOX GEP, 1955, J ROY STAT SOC B, V17, P1
  • [7] CHOU M, 2009, 16 C RETR OPP INF MO
  • [8] Comets E, 2001, J Biopharm Stat, V11, P107, DOI 10.1081/BIP-100107652
  • [9] Crow JF, 1999, GENETICS, V152, P821
  • [10] Evaluation of uncertainty parameters estimated by different population PK software and methods
    Dartois, Celine
    Lemenuel-Diot, Annabelle
    Laveille, Christian
    Tranchand, Brigitte
    Tod, Michel
    Girard, Pascal
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2007, 34 (03) : 289 - 311